Aimmune Therapeutics Inc. | Mutual Funds
Mutual Funds that own Aimmune Therapeutics Inc.
SPDR S&P Biotech ETF
1,721,050
2.94%
4,428
0.82%
09/06/2018
T Rowe Price Health Sciences Fund
1,213,888
2.08%
12,527
0.27%
06/30/2018
Fidelity Select Biotechnology Portfolio
1,189,521
2.02%
-68,713
0.36%
07/31/2018
T Rowe Price New Horizons Fund
1,122,218
1.92%
8,600
0.13%
06/30/2018
Catalyst Eventide Gilead Fund
1,077,000
1.84%
0
1.62%
06/29/2018
Vanguard Small Cap Index Fund
1,020,148
1.75%
11,338
0.03%
07/31/2018
Vanguard Total Stock Market Index Fund
988,506
1.69%
0
0%
07/31/2018
Eagle Small Cap Growth Fund
964,906
1.65%
-590,828
0.47%
06/29/2018
iShares Russell 2000 ETF
906,433
1.55%
-483
0.05%
09/06/2018
iShares Nasdaq Biotechnology ETF
673,473
1.14%
-8,799
0.19%
09/06/2018
| Address |
8000 Marina Boulevard
Brisbane California 94005
United States
|
|
Employees
|
- |
| Website |
http://www.aimmune.com |
| Updated |
07/08/2019 |
| Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. |
